ReviewInfectious agents and cancer2024
Prevalence of HPV in anal cancer: exploring the role of infection and inflammation.
Review in Infectious agents and cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Genotyping and Cytology Co-Testing for Anal Cancer Screening: Exploratory Evaluation of Cumulative HPV Genotype Burden as a New Potential Marker for Risk Stratification.Diagnostics (Basel, Switzerland) · 2026Article
- Real-World Outcomes of Chemoradiotherapy for Anal Squamous Cell Carcinoma: Insights from Northeast India.Indian journal of surgical oncology · 2026Article
- Repeated Detection of Vaccine-Preventable Anal HPV Genotypes in a Screened Cohort: A Retrospective Observational Study.Pathogens (Basel, Switzerland) · 2026Observational
- HPV-Related Disease: Gynecologists' Leadership in Patient-Centered Multidisciplinary Care.Cancers · 2026Article
- HPV-related cancer prevention in Spain: progress and remaining challenges in vaccination, screening, and surveillance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- HPV awareness and anal cancer prevention among sexual minority men living with HIV in Nigeria: insights from an affirming clinical setting.Sexual health · 2026Article
- Hypothesis: HPV E6 and COVID spike proteins cooperate in targeting tumor suppression by p53.Oncotarget · 2026Article
- Heterogeneity in health anxiety among medical students and HPV testing acceptability: the mediating role of eHealth literacy from a person-centered perspective.Frontiers in public health · 2026Article
- Development and internal validation of a vaginal microecology-based multivariable prediction model for persistent high-risk human papillomavirus infection: a retrospective study.Frontiers in medicine · 2026Article
- Article
- Anti-HPV gel versus interferon α-2b gel as adjuvant therapy after LEEP for HSIL with HR-HPV infection on clinical outcomes, vaginal microecology, and biomarkers of proliferation and immunity.Frontiers in oncology · 2026Article
- HPV-driven inflammatory pathways in ovarian carcinogenesis: molecular mechanisms and emerging therapeutic interventions.Journal of ovarian research · 2025Review
- Article
- HPV16 E6 and E7 Genetic Variability in Oral and Anal Samples from HIV-Positive MSM.Pathogens (Basel, Switzerland) · 2025Article
- The Role of Human Papillomavirus Genotypes on Anal Squamous Intraepithelial Lesions Among Gay, Bisexual and Other Men Who Have Sex With Men Living With HIV: Beyond HPV-16.Journal of medical virology · 2025Article
- Prevalence and Associated Factors for HPV in People Living with HIV: Are INSTIs Protective Against HPV-16? The GAIA Study.Viruses · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anal cancer incidence is rising globally, driven primarily by human papillomavirus (HPV) infection. HPV, especially high-risk types 16 and 18, is considered a necessary cause of anal squamous cell carcinoma. Certain populations like people living with HIV, men who have sex with men, inflammatory bowel disease patients, smokers, and those with compromised immunity face elevated risk. Chronic inflammation facilitates viral persistence, cell transformation, and immune evasion through pathways involving the PD-1/PD-L1 axis. HIV coinfection further increases risk by impairing immune surveillance and epithelial integrity while promoting HPV oncogene expression. Understanding these inflammatory processes, including roles of CD8 + T cells and PD-1/PD-L1, could guide development of immunotherapies against anal cancer. This review summarizes current knowledge on inflammation's role in anal cancer pathogenesis and the interplay between HPV, HIV, and host immune factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.